Cookson Peirce & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Cookson Peirce & Co’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-50,000	Closed	-$65K	–	231
2023 Q2	$65K	Buy	+50,000	New	+$68.3K	﹤0.01%	212
2022 Q4	–	Sell	-12,000	Closed	-$59K	–	219
2022 Q3	$59K	Buy	+12,000	New	+$61.6K	﹤0.01%	183
2021 Q1	–	Sell	-99,030	Closed	-$1.54M	–	204
2020 Q4	$1.54M	Buy	+99,030	New	+$1.16M	0.11%	84
2018 Q2	–	Sell	-27,650	Closed	-$525K	–	160
2018 Q1	$525K	Buy	27,650 +2,510	+10%	+$53.7K	0.05%	111
2017 Q4	$412K	Sell	25,140 -21,060	-46%	-$313K	0.04%	130
2017 Q3	$693K	Buy	46,200 +10,210	+28%	+$113K	0.07%	103
2017 Q2	$317K	Buy	+35,990	New	+$231K	0.04%	132

Other funds holding SGMO

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMU

Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cookson Peirce & Co's SGMO Position: Q3 2023 in Review

Cookson Peirce & Co sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2023, closing a stake of 50,000 shares — an estimated $65K sold.

Cookson Peirce & Co first reported a position in SGMO in Q2 2017 and held it in 7 quarters. The position peaked at $1.54M in Q4 2020. 134 funds tracked by Wall St. Rank hold SGMO as of Q3 2023.

Cookson Peirce & Co reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2023 after selling out during the quarter.
Cookson Peirce & Co sold 50,000 SANGAMO THERAPEUTICS INC shares in Q3 2023, an estimated $65K.
Cookson Peirce & Co first reported a position in SANGAMO THERAPEUTICS INC in Q2 2017 and held it in 7 quarters.
Cookson Peirce & Co's SANGAMO THERAPEUTICS INC position peaked at $1.54M in Q4 2020.
134 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2023.

Based on Cookson Peirce & Co's 13F filing for Q3 2023, filed 7 Nov 2023.